Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis

NCT03786380 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT03786380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03786380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis
Lead sponsor
Allergan
Phase
Phase 3
Overall status
Terminated
Start date
December 20, 2018
Completion date
October 5, 2020
Enrollment
202 (actual)
Sites
486

Conditions

As the registry lists them; a condition with its own page is linked.

gastroparesis